1. Home
  2. PRAX vs TXG Comparison

PRAX vs TXG Comparison

Compare PRAX & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$254.33

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$70.90

Market Cap

8.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
TXG
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.5B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
PRAX
TXG
Price
$254.33
$70.90
Analyst Decision
Strong Buy
Buy
Analyst Count
21
19
Target Price
★ $650.00
$77.00
AVG Volume (30 Days)
481.4K
★ 3.8M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 76.97
EPS
N/A
★ N/A
Revenue
N/A
★ $245,893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$39,256.17
$10.13
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 68.06
52 Week Low
$154.46
$12.34
52 Week High
$392.70
$102.81

Technical Indicators

Market Signals
Indicator
PRAX
TXG
Relative Strength Index (RSI) 38.28 45.30
Support Level $237.78 $56.98
Resistance Level $356.02 $102.81
Average True Range (ATR) 12.32 7.54
MACD 2.23 -1.56
Stochastic Oscillator 32.24 10.29

Price Performance

Historical Comparison
PRAX
TXG

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Share on Social Networks: